Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–69 of 69 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lou Gehrig Disease Clear all
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

NCT05039099
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AP-101, Placebo
Drug
Lead sponsor
AL-S Pharma
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 7, 2026, 6:51 AM EDT
Recruiting Not applicable Interventional

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Dexpramipexole in ALS

NCT01281189
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 2Phase 3 Interventional

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

NCT00706147
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Arimoclomol, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 7, 2026, 6:51 AM EDT
Suspended Phase 1 Interventional

Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis

NCT01082653
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous bone marrow-derived stem cells
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of High Dose CoQ10 in ALS

NCT00243932
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Interventions
coenzyme Q10, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
19
States / cities
Little Rock, Arkansas • San Francisco, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 7, 2026, 6:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Developing New Ways to Detect Respiratory Impairment Early in ALS

NCT07844590
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 6:51 AM EDT
Completed No phase listed Observational

Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

NCT02686268
View directory record Official record
Conditions
C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Baltimore, Maryland • Amherst, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

NCT02039401
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VM202
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
21 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen G DNL343

NCT05842941
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL343, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 2Phase 3 Interventional

Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement

NCT00386464
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
noninvasive positive pressure ventilation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2007 · Synced Oct 7, 2026, 6:51 AM EDT
No Longer Available No phase listed Expanded access

IC14 for ALS Patients Expanded Access

NCT04309604
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
IC14
Biological
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 7, 2026, 6:51 AM EDT
Completed No phase listed Observational Results available

A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients

NCT00786032
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
BCI Device
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 79 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
West Haven, Connecticut • Albany, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 7, 2026, 6:51 AM EDT
No Longer Available No phase listed Expanded access

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

NCT06069934
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine
Drug
Lead sponsor
Prilenia
Industry
Eligibility
18 Years and older
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Early Phase 1 Interventional

Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study

NCT03707795
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Drug
Lead sponsor
Edward Kasaraskis
Other
Eligibility
20 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

NCT00116558
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Early NIPPV, Standard NIPPV
Device
Lead sponsor
Edward Kasaraskis
Other
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
12
States / cities
Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 7, 2026, 6:51 AM EDT
Recruiting Not applicable Interventional

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

NCT06649955
View directory record Official record
Conditions
ALS - Amyotrophic Lateral Sclerosis
Interventions
Multi-site direct current stimulation (DCS)
Device
Lead sponsor
PathMaker Neurosystems Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

Mexiletine for the Treatment of Muscle Cramps in ALS

NCT01811355
View directory record Official record
Conditions
Muscle Cramps in Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
Bjorn Oskarsson, MD
Other
Eligibility
21 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Chester, California • La Jolla, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 1Phase 2 Interventional

Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis

NCT00956488
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Lou Gehrig's Disease
Interventions
Treadmill Exercise
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 7, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

NCT02781454
View directory record Official record
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Orange, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 7, 2026, 6:51 AM EDT